Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule.
DEA is amending its regulations to require additional recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB) for which an application has been approved under the Federal Food, Drug, and Cosmetic Act. DEA makes these changes under section 4 of the "Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000." These additional requirements are necessary to protect against the diversion of GHB for illicit purposes.
D002492:Central Nervous System Depressants / Q000009:adverse effects / Q000145:classification; D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D005568:Forms and Records Control / Q000331:legislation & jurisprudence*; D006801:Humans; D006885:Hydroxybutyrates / Q000009:adverse effects* / Q000145:classification; D011902:Rape / Q000331:legislation & jurisprudence / Q000517:prevention & control; D019966:Substance-Related Disorders / Q000517:prevention & control; D014481:United States
D002492:Central Nervous System Depressants; D006885:Hydroxybutyrates